Introduction: Thymic epithelial tumors (TETs) including thymoma and thymic carcinoma are rare tumors with little data available to guide treatment. Immunotherapy with checkpoint blockade has shown promising activity, but data regarding the expression patterns and prognostic implications of programmed death 1 (PD-1) and its ligand (PD-L1) in TETs have yielded conflicting results. Intratumoral heterogeneity of PD-1/L1 expression has been shown in other cancers, but has not been described in the TET literature.
Introduction
Thymic epithelial tumors (TETs), including thymoma and thymic carcinoma, are rare tumors that originate in the thymus. 1, 2 The WHO classification divides TET into thymoma (types A, AB, B1, B2, and B3) and thymic carcinoma (type C in the 2004 classification). [3] [4] [5] Thymic carcinomas represent 15% to 20% of all thymic neoplasms, and the 5-year survival rate of 53% is significantly lower than that for thymoma which is close to 90%.
Surgical resection is the only curative intervention for patients with TET, and completeness of surgery is the most important predictor of survival. 7, 9, 10 Radiation is typically offered in combination with chemotherapy for patients with unresectable disease. 11, 12 Patients with metastatic disease are treated with platinum-based chemotherapy regimens. [13] [14] [15] [16] There are no well-studied standard treatment options for patients in the secondline setting, although the tyrosine kinase inhibitor sunitinib has shown activity in patients who progressed after platinum-based chemotherapy. 17 There is clearly an unmet need for additional treatment options for this patient population. Immunotherapy with antibodies to programmed death 1 (PD-1) and its ligand, programmed death ligand 1 (PD-L1), has changed the landscape of treatment options for patients with many tumors, including melanoma, head and neck carcinoma, and NSCLC. [18] [19] [20] The search for additional treatment options for patients with TET has led to several studies evaluating the expression of PD-L1 in TET, as high expression of PD-L1 has been found to be predictive of benefit in patients with NSCLC treated with checkpoint inhibitors in the firstline setting. 20 Case reports have shown responses in both thymoma and squamous cell thymic carcinoma to the checkpoint inhibitor pembrolizumab. 21, 22 The efficacy of immunotherapy is currently being evaluated in a phase 2 trial of pembrolizumab in patients with thymic carcinoma, with early results presented at the American Society of Clinical Oncology Meeting 2016 showing promising activity with a 22.5% response rate. 23 Studies have thus far shown high rates of PD-L1 expression in TET, but have reported conflicting results in terms of the prognostic and predictive value of PD-L1 and PD-1 expression, perhaps due to variabilities of antibodies used and methods of PD-L1 expression scoring. Two studies that have shown a prognostic value of PD-L1 demonstrated opposing results, with Padda et al. 24 finding that high PD-L1 expression was associated with a worse prognosis and Yokoyama et al. 25 finding that high PD-L1 was associated with a better prognosis. Additionally, there are several limitations of PD-L1 expression as a biomarker including variations between assays as well as inter-and intratumoral heterogeneity. The most common assays used include 22C3 (Dako North America, Carpinteria, California), 28-8 (Dako), SP263 (Ventana Medical Systems, Tucson, Arizona) and SP142 (Ventana). The recently published Blueprint PD-L1 Immunohistochemistry (IHC) Assay Comparison Project offers an extensive review of these assays, and shows considerable variability in expression patterns between some of the PD-L1 assays in NSCLC, especially SP-142. 26 Separately, intratumoral heterogeneity in PD-L1 expression has been reported in NSCLC. 27 Therefore, we set out to study the expression patterns, prognostic value, and heterogeneity of PD-L1 and PD-1 expression by IHC among resected TET samples at our institution using the 22C3 antibody which is used in the predictive, U.S. Food and Drug Administration (FDA)-approved companion diagnostic assay for use in detecting PD-L1 expression in NSCLC, where pembrolizumab is approved in the first-line setting in patients with high PD-L1 expression. 20 We also sought to examine associations between PD-1 and PD-L1 expression and stage, grade, survival, and diagnosis of myasthenia gravis (MG), as the potential for exacerbating autoimmune conditions associated with TET may limit the utility of checkpoint inhibitors in patients with these diseases. 4 The study was approved by the institutional review board.
Materials and Methods

Patients
Immunohistochemistry
Formalin-fixed, paraffin-embedded tissue specimens obtained from surgical resections were examined. PD-1 and PD-L1 expression patterns were assessed by IHC on tumor samples by a pathologist blinded to clinical outcomes. The PD-1 antibody used was NAT105 (1:100, Abcam, Cambridge, United Kingdom) and PD-L1 antibody used was 22C3 (Merck Research Laboratories, Palo Alto, California). Expression was graded in a semiquantitative scoring system from 0 to 5 (0 indicating no expression, 5 indicating high expression) as described elsewhere.
28-30
Statistical Considerations
Demographic and clinical factors were summarized separately by PD-L1 (positive versus negative, high/ moderate versus low) and PD-1 (positive versus negative, high/moderate versus low) status separately. High/moderate positivity was determined as an expression score of 3 or greater by IHC, and low expression of 1 or 2 by IHC. Selected factors (WHO grade, stage, smoker, MG diagnosis, and recurrence) were compared between groups using chi-square tests; p values were adjusted for multiple comparisons using Hochberg's procedure. Estimates of OS were calculated using the Kaplan-Meier method and differences in the curves between groups were assessed using the log-rank test. In addition, hazard ratios (HRs) and 95% confidence intervals (CIs) from univariable (unadjusted) Cox proportional hazards models were calculated; due to the small sample sizes (both overall and number of events), additional covariate adjustment was not performed. All analyses were performed using SAS/STAT software, Version 9.4 of the SAS System for Windows (SAS Institute Inc., Cary, North Carolina).
Results
Patient Characteristics
Tumor specimens from 35 patients with thymoma and thymic carcinoma undergoing surgical resection were collected at our institution. Patient characteristics are shown in Table 1 . As would be expected from a cohort of patients undergoing resection, the majority of patients had early-stage disease; they included predominantly thymoma with only 3 thymic carcinoma patients. Median follow-up time was 6.2 years (25th, 57th percentile: 2, 8 years, respectively), at which time 25 patients had died and 10 patients were alive.
Immunohistochemical Detection of PD-1 and PD-L1
Expression patterns of PD-L1 and PD-1 by IHC are also depicted in Table 1 . PD-L1 was present in the majority of specimens examined, including 81% of thymoma and 100% of thymic carcinoma samples. PD-1 expression was present in 81% of patients with thymoma but only 33% of patients with thymic carcinoma. When only high/moderate levels of PD-L1 and PD-1 were assessed ( 3þ by IHC), 57% of patients had high/moderate PD-L1 expression whereas only 31% of all patients had high/moderate PD-1 expression. Unlike prior studies, the expression of PD-L1 was not associated with WHO grade (A, AB, B1 versus B2, B3, C) (p ¼ 0.99) or stage (1/2 versus 3/4) (p ¼ 0.51). 31 As seen in Table 2 
Prognostic Value of PD-1 and PD-L1
Kaplan-Meier curves for the overall population are shown in Figure 1 . There was no significant difference in OS seen in patients with PD-L1 expression (p ¼ 0.10, log-rank test, Fig. 1 ). Survival was not significantly 
Intratumor Heterogeneity in PD-L1 and PD-1 Expression
Three patients had multiple slides prepared from the same tumor specimen analyzed for PD-L1 and PD-1 expression by IHC. All three patients had a diagnosis of thymoma. Table 3 and Figure 2 show the results of expression patterns, which were different for two of three patients, including a marked difference in both PD-L1 and PD-1 expression in two of three patients. In comparison, there were relatively minor changes in histology between specimens (patient OSU 07 grade A and B1; patient OSU 26 grade B1 and B2; and patient OSU 32 B2 and B3). This confirms the finding of variable PD-L1 expression in studies in other tumors, and shows for the first time intratumoral heterogeneity in PD-1/L1 expression in thymoma. 27 
Discussion
Immunotherapy with checkpoint blockade has profoundly changed the management of patients with a variety of malignancies, and is now standard of care first-line therapy for select patients with NSCLC whose tumors exhibit PD-L1 expression above a certain threshold (50% tumor proportion score). [18] [19] [20] [32] [33] [34] PD-1/L1 expression has been found in a number of different cancers; however, the utility of either PD-1 or PD-L1 as a prognostic biomarker remains unclear. In a meta-analysis including 29 studies covering a total of 7319 patients with 12 types of epithelial-originated malignancies, Zhang et al. 35 reported that positive PD-L1 expression and positive PD-1 expression were both associated with shorter OS. However, several other studies have found opposing results for different tumors and even within tumor subtypes. Within early stage lung cancer, studies have shown a correlation with PD-L1 and either poor prognosis or good prognosis, whereas larger studies have shown no prognostic value of PD-L1. [36] [37] [38] [39] Similarly, there are studies showing prognostic value of PD-L1 and PD-1 in pancreatic cancer, colon cancer, and pulmonary neuroendocrine cancer, among others. [40] [41] [42] [43] [44] The efficacy and safety of immunotherapy was evaluated in a recently published phase 2 trial of pembrolizumab in patients with thymic carcinoma, with a 22.5% response rate, including one complete response; however, autoimmune-related toxicities developed in several patients. 23 Although immunotherapy appears to be a promising treatment for patients with thymoma and thymic carcinoma, the risk of immune-related adverse events and the lack of response in the majority of patients show the necessity of investigating robust biomarkers predictive of response. To date there have been nine prior publications evaluating the expression patterns of PD-L1 in thymoma and thymic carcinoma, and five publications evaluating PD-1 in this population (summarized in Table 4) . 24, 25, 31, 45, [46] [47] [48] [49] [50] The data so far are conflicting in terms of the prognostic value of either PD-L1 or PD-1 and any association between expression status and tumor grade or stage. Across all studies, high proportions of tumors from patients with thymoma and thymic carcinoma expressed PD-L1 and PD-1. However, significant variation between the studies exists regarding the association between PD-1/L1 expression and OS. For example, Padda et al. 24 assessed PD-L1 expression on tissue microarray of 65 thymoma and 4 thymic carcinoma samples and found that higher PD-L1 expression was associated with higher WHO histologic grade (B2, In unadjusted analysis, no difference in OS was noted, but in age and gender adjusted analysis PD-L1high versus PD-L1 low had worse OS (p ¼ 0.035), but included both thymoma and thymic carcinoma together. When adjusted for stage, no significant association with OS was noted (p ¼ 0.071).
g Reported for thymoma cohort, since no difference able to report since three thymic carcinoma patients had PD-L1 expression. PD-L1, programmed death ligand 1; PD-1, programmed death 1; NA, not available; OS, overall survival; HR, hazard ratio. reported that high PD-L1 expression was associated with a better prognosis, including longer OS and progressionfree survival. Katsuya et al. 31 reported expression of PD-L1 in 101 thymomas and 38 thymic carcinomas and found higher PD-L1 expression in thymic carcinoma compared to thymoma (p ¼ 0.006), but unlike the prior studies, PD-L1 was not associated with OS (HR ¼ 0.99, 95% CI: 0.35-2.73, p ¼ 0.987). The same group later evaluated 30 patients with thymoma and thymic carcinoma who had received chemotherapy and found no association between PD-L1 expression and clinical benefit from chemotherapy. 45 Marchevsky and Walts 46 reported expression of PD-L1 in 92% of thymomas and 50% of thymic carcinomas and found higher PD-L1 expression in B2/3 thymoma compared to AB and B1 thymoma. The authors also reported that 90% of nonneoplastic thymic tissue was positive for PD-L1, in contrast to the findings from Padda et al. 24 Most recently Weissferdt et al. 48 reported expression of PD-L1 and PD-1 patterns of 74 thymoma and 26 thymic carcinoma samples and found that PD-1-positive thymic carcinomas were associated with a higher stage, but there was no association between PD-1 and PD-L1 expression with survival in either the thymoma or thymic carcinoma patients.
One possible explanation for the variable findings of PD-L1 and PD-1 expression between studies is the use of different antibodies for IHC detection. The recently reported data from phase 1 of the Blueprint PD-L1 IHC Assay Comparison Project showed significant variation in tumor PD-L1 detection in lung cancer specimens between available PD-L1 assays, especially the SP-142 assay. 26 Additionally, four of previously mentioned studies used the E1L3N antibody which has been shown to have lower sensitivity than other available antibodies. 51 To determine whether the variations of IHC expression may be due to the different assays used, we used the 22C3 antibody which is employed in an FDA approved assay to guide treatment in NSCLC based on the results of several trials. 20, 52 Using the 22C3 antibody, we confirmed high expression patterns for the entire population of PD-L1 (n ¼ 29, 83%) and PD-1 (n ¼ 27, 77%). Expression of PD-L1 was present in 81% of thymoma patients and all three thymic carcinoma patients (100%), whereas expression of PD-1 was lower in thymic carcinoma patients (31%) than thymoma patients (81%).
We were unable to replicate the results by Padda et al. 24 of an association between high PD-L1 expression and worse clinical outcomes (p ¼ 0.10, log-rank test; p ¼ 0.12 after three thymic carcinoma patients were excluded). Unlike prior studies, neither PD-L1 expression nor high levels of PD-L1 expression was associated with tumor grade. 24, 31 Whereas Weissferdt et al. 48 reported that PD-1 was associated with higher stage thymic carcinomas, we found higher PD-1 expression to be associated with lower WHO histologic grade (p ¼ 0.03). The difference may be due to different assay used and the fact that our trial included mostly thymoma patients. Neither study showed an association between PD-1 and survival.
Heterogeneity between primary tumor site and metastatic site has been reported in melanoma and renal cell carcinoma, and intratumoral heterogeneity has been shown in NSCLC. 27, [53] [54] [55] Our study adds to the literature regarding heterogeneity of expression patterns of PD-L1 and PD-1 in tumors. By evaluating different sections of the same tumor specimen of three patients, we showed variable expression of both PD-L1 and PD-1 in two of three patients with thymoma. The variation was significant for both PD-L1 and PD-1. This variability further shows the limitations of basing treatment strategies on an assay that is not constant within tumors or over time. For example, Katsuya et al. 45 analyzed serial tumor samples from six patients pre-and post-chemotherapy and showed that PD-L1 and PD-1 expression increased after chemotherapy, with all six samples being positive for both PD-L1 and PD-1 after treatment with chemotherapy with doxorubicin and paclitaxel, compared to 67% (4 of 6) for PD-L1 pre-chemotherapy and 33% (2 of 6) of PD-1 samples pre-chemotherapy using the E1L3N antibody.
Our study had several strengths and some limitations. Strengths of this study include the use of resection specimens that assure ample tissue for IHC staining which is not always the case with biopsy specimens that might be limited by lack of tissue and which may impact PD-L1 assessment, as noted in prior studies. 45 An additional strength of this study was the use of the 22C3 antibody, which is employed in an FDA-approved assay for use in NSCLC. Limitations of this study include the small sample size and the inclusion of mostly early-stage patients with thymoma. Although the predictive value of PD-L1 expression has been determined by tumor proportion score in NSCLC, this scoring system has not yet been used in thymoma or thymic carcinoma, and the use of expression score by IHC in the current study is consistent with prior studies in thymoma as well as research in melanoma where the melanoma (MEL) scale has been utilized. 20, 56 Further research is needed to determine whether tumor proportion score has a role in tumors other than NSCLC. Overall, in a rare disease with limited reports in the literature, these data expand upon current knowledge while also adding new information regarding intratumor heterogeneity of PD-L1 and PD-1 expression.
In conclusion, the current study confirmed the finding of high levels of PD-L1 expression in thymoma and thymic carcinoma using an approved assay. Our study also showed no statistically significant differences in survival in patients with high PD-L1 or PD-1 expression. We found that high PD-1 expression was associated with lower histologic grade but found no relationship between either PD-L1 or PD-1 and stage or diagnosis of MG. Finally, in a limited subset of patients there was significant intratumoral heterogeneity in both PD-1 and PD-L1 expression.
